To reinforce the discriminatory power of our methylation biomarkers for adenomas, the methylation level of the 10 CTCF-binding sites was further determined in 90 samples by increasing the proportion of adenoma samples (20 normal tissues, 57 adenomas, six Stage I CRC, and seven Stage II CRC) by mass spectrometry analysis. This evidence concerns the gene CTCF and colorectal carcinoma.